Hudson Executive Capital Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
TVTY
Tivity Health, Inc. Common Stock
TVTY
|
+$40.6M |
| 2 |
CTLP
Cantaloupe
CTLP
|
+$21.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AtriCure
ATRC
|
+$2.86M |
| 2 |
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
|
+$79.4K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 36.75% |
| 2 | Industrials | 18.59% |
| 3 | Healthcare | 12.13% |
| 4 | Technology | 5.62% |
| 5 | Materials | 2.78% |
Similar funds
Hudson Executive Capital's Q3 2019 Portfolio in Review
As of Q3 2019, Hudson Executive Capital held 12 positions worth $1.32B, up 27% from $1.04B the previous quarter. Its ten largest holdings account for 99% of the portfolio.
Hudson Executive Capital deployed $250M of net new capital in Q3 2019, opening 1 new position and adding to 3 existing holdings. Its largest new stake was Tivity Health, Inc. Common Stock: 2,346,560 shares worth $39M.
By sector, the portfolio is most concentrated in Financials at 37% of assets, down from 48% a quarter earlier, followed by Industrials and Healthcare.
On the sell side, the largest reduction was AtriCure, an estimated $2.86M trimmed.
- Hudson Executive Capital's largest Q3 2019 buy was Tivity Health, Inc. Common Stock: 2,346,560 shares worth $39M.
- Hudson Executive Capital added most to Cantaloupe in Q3 2019, an estimated $21.1M increase.
- Hudson Executive Capital's biggest Q3 2019 reduction was AtriCure, cutting an estimated $2.86M.
- Hudson Executive Capital's ten largest holdings make up 99% of its $1.32B portfolio in Q3 2019.
- Hudson Executive Capital opened 1 new position and closed 0 in Q3 2019.
- Hudson Executive Capital's portfolio value rose 27% quarter-over-quarter to $1.32B.
Based on Hudson Executive Capital's 13F filing for Q3 2019, filed 14 Nov 2019.